CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. - Wikidata - awgldk - TriplyDB

CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative.

CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative.

http://www.wikidata.org/entity/Q40591372

about

Oncolytic viruses as therapeutic cancer vaccines Improved systemic delivery of oncolytic reovirus to established tumors using preconditioning with cyclophosphamide-mediated Treg modulation and interleukin-2 Dendritic cells are defective in breast cancer patients: a potential role for polyamine in this immunodeficiency Regulatory T Cells in the Tumor Microenvironment and Cancer Progression: Role and Therapeutic Targeting Exploiting the Immunomodulatory Properties of Chemotherapeutic Drugs to Improve the Success of Cancer Immunotherapy Prognostic value of tumor-infiltrating FoxP3+ regulatory T cells in cancers: a systematic review and meta-analysis Adoptive immunotherapy for acute leukemia: New insights in chimeric antigen receptors Relevance of tumor-infiltrating lymphocytes in breast cancer Cancer immunotherapy via combining oncolytic virotherapy with chemotherapy: recent advances Regulatory T cell: a protection for tumour cells Neoplastic "Black Ops": cancer's subversive tactics in overcoming host defenses Tumor microenvironment: regulatory cells and immunosuppressive cytokines Endpoints, patient selection, and biomarkers in the design of clinical trials for cancer vaccines Targeting and utilizing primary tumors as live vaccines: changing strategies Harnessing immunosurveillance: current developments and future directions in cancer immunotherapy Cancer vaccines An update on vaccine therapy and other immunotherapeutic approaches for glioblastoma Suppression, subversion and escape: the role of regulatory T cells in cancer progression Immunomodulatory effects of low dose chemotherapy and perspectives of its combination with immunotherapy Serial low doses of sorafenib enhance therapeutic efficacy of adoptive T cell therapy in a murine model by improving tumor microenvironment Cross-talk between microbiota and immune fitness to steer and control response to anti PD-1/PDL-1 treatment Update on immune checkpoint inhibitors in gynecological cancers Prospects for exosomes in immunotherapy of cancer Chemotherapeutic agents in noncytotoxic concentrations increase antigen presentation by dendritic cells via an IL-12-dependent mechanism In vivo expansion of naïve CD4+ CD25(high) FOXP3+ regulatory T cells in patients with colorectal carcinoma after IL-2 administration Randomized multicenter trial of the effects of melanoma-associated helper peptides and cyclophosphamide on the immunogenicity of a multipeptide melanoma vaccine The safety profile of cyclophosphamide in multiple sclerosis therapy.The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide.Inability to mediate prolonged reduction of regulatory T Cells after transfer of autologous CD25-depleted PBMC and interleukin-2 after lymphodepleting chemotherapy Cyclophosphamide chemotherapy sensitizes tumor cells to TRAIL-dependent CD8 T cell-mediated immune attack resulting in suppression of tumor growth.A phase II open label trial evaluating safety and efficacy of a telomerase peptide vaccination in patients with advanced hepatocellular carcinoma Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells Immunological factors relating to the antitumor effect of temozolomide chemoimmunotherapy in a murine glioma model.The role of regulatory T cells in cancer.Cyclophosphamide induces bone marrow to yield higher numbers of precursor dendritic cells in vitro capable of functional antigen presentation to T cells in vivo.Phenotype, functions and fate of adoptively transferred tumor draining lymphocytes activated ex vivo in mice with an aggressive weakly immunogenic mammary carcinoma Potent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer.Paclitaxel enhances early dendritic cell maturation and function through TLR4 signaling in mice A reduction of recipient regulatory T cells by cyclophosphamide contributes to an anti-tumor effect of nonmyeloablative allogeneic stem cell transplantation in mice.Immunotherapy converts nonimmunogenic pancreatic tumors into immunogenic foci of immune regulation

P2860

Q21245758-BAF164B7-A9B4-48E6-BF6F-01B6F1458AC4 Q24612603-1017407F-5A8D-4AB2-81F0-5C0F9FC1D6AE Q24810259-F7AA6A0F-A255-4B00-81A8-B700560D671C Q26742012-AF12F21E-0ED5-410F-AC8E-EA043121EF21 Q26779184-C8979DC0-04E0-45A6-B2EF-81F6072677B1 Q26783675-C80A234F-722F-46CA-8575-2C21C2F20662 Q26795540-CE06E1F1-4166-4191-8C51-66AD0F17255C Q26795598-A41B4AD5-61B8-4C36-A843-125F4C438BBE Q26863779-9CDE8808-0640-44DE-BA46-F49F78A7C3AD Q26991447-7F26DD7A-9E37-4550-97AB-61867600F8EF Q27001081-BA5D0AA5-C20C-4B8E-99D5-B4364367E8D7 Q27007772-836C0254-6A41-475F-B9B2-59A0CB47581C Q27008070-9E74AB7C-9B48-4517-A12D-7C19A3F9809E Q27009348-87D48294-8B54-4A59-970E-B39ECC6A391F Q27021570-A49EFBE1-F210-444A-8903-94AA1D066677 Q27024438-71E0CFD0-E327-4BB2-BC57-838D01603C8D Q27024830-F383B51B-6D61-449C-97C5-7FE7572E84B4 Q27026151-1307F307-B25E-4FA5-9364-DE3562F2BDD1 Q27027093-E6D3812C-0AFF-4563-B080-16073909725B Q27335748-D73E5BC1-96DF-4EB3-954A-5CCDF1078AE8 Q28076294-A62FF29E-14FB-4673-9A79-5E224E42476D Q28076497-0AB3722F-F7BB-4F7E-BF21-3CDDCFE06236 Q28248098-47076632-387A-4D05-9FC8-05CC58A6E009 Q28384980-29B47453-F872-46BD-A8BC-6522EEB8030C Q28732675-E81A8B88-C06B-4A0E-9841-7464537C0826 Q30425914-EDF07536-81BA-485B-9499-4CA8ACBA3A6F Q31105891-CC5F77C0-57A4-4D3A-8F3C-03CAD67ABE31 Q31144277-3B6CEBD6-B340-4C86-AC02-0390788C4D70 Q33282703-A6B4F032-862E-41C0-8783-36FC319EBCF5 Q33502208-4A8EBA6B-6BCA-4AFE-A66D-AEC146A8A0A7 Q33579629-87458A3A-A89C-4341-9CCF-4B1727F5E57E Q33604925-E0158A0C-8056-4943-9F70-D8E376633BEE Q33613430-30612A82-879D-4DD3-9355-E6EABA5DF07B Q33631986-EE5C7312-2361-4711-B3D1-AF25F2C2F370 Q33653210-D72DDF54-52A9-4B1A-847F-5CC595FD9BB0 Q33738279-E35BCAB9-E134-4676-BD82-21800008205F Q33780751-288961D8-9B68-4D2C-81E5-70989768A36C Q33823499-2C8E8B06-4F02-43BC-B673-1513E234761B Q33829731-18826AC7-A2B3-44BB-9BCE-CC5C3288A334 Q33848077-35D9E2C1-801B-4977-A144-E53964FB091F

P2860

CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative.

http://www.wikidata.org/entity/Q40591372

description

2004 nî lūn-bûn

@nan

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

2004年论文

@zh

2004年论文

@zh-cn

name

CD4+CD25+ regulatory T cells s ...... blished tumors to be curative.

@en

type

label

CD4+CD25+ regulatory T cells s ...... blished tumors to be curative.

@en

prefLabel

CD4+CD25+ regulatory T cells s ...... blished tumors to be curative.

@en

P1433

Q40591372-9F045D6C-AB3E-4322-A39D-AC454B9758EF

P1476

Q40591372-942B9135-552C-4A46-A848-B314A4629735

P2093

Q40591372-2279BACE-DBB9-49CD-AC26-11165E41C42F

Q40591372-406291EC-05E9-422C-9A52-9AC761F4EF34

Q40591372-4141109A-3E87-4E80-A115-44459848AF7C

Q40591372-6E14943E-7CE0-447E-B8DD-C4841FDC31DA

Q40591372-83425199-E1EE-427E-A2A3-B3229B90D099

Q40591372-91278773-5F84-4B98-9D57-4B7AB86410F2

Q40591372-BC672836-3592-4AB7-AADB-4FC2472A50B4

Q40591372-D9632A34-0ABE-49AE-87E9-E31BF187E21C

P304

Q40591372-B9640F26-CED7-4B1E-B2AB-29AA27137FF1

P31

Q40591372-482A2903-DCE8-4B15-8FB4-7502AEE01EC9

P356

Q40591372-BD892A75-956B-4117-A404-79D16287AF94

P407

Q40591372-A87C57DD-1465-419A-A4F2-5B0D0E39B1CA

P433

Q40591372-CF5D9372-1789-44AD-88D2-6D13F4BE888B

P478

Q40591372-76DEB0D4-791F-4A1D-B7A2-53EC36620C13

P50

Q40591372-39BD65B1-B719-4F0A-B061-387C2AFB1FB9

Q40591372-458265D0-C2BF-46DD-8402-B1C4C94DA4CF

Q40591372-89835EB5-19BE-4E55-BD32-536E05C05ABB

Q40591372-FDAED5B5-23F7-4B96-8CE6-33DA65FFD998

P577

Q40591372-948BB455-C849-4FBF-BCC6-02F06A8F40C4

P5875

Q40591372-9DC0F5CF-77BB-4A51-AA79-ED152984E557

P698

Q40591372-D0416C8D-ABB6-46F7-B346-E5C603EB9264

P921

Q40591372-F831D801-7D20-4DE0-B037-44C32C7787C6

P356

P1433

European Journal of Immunology

P1476

CD4+CD25+ regulatory T cells s ...... blished tumors to be curative.

@en

P2093

Arnaud Parcellier

http://www.w3.org/2001/XMLSchema#string

Bernard Bonnotte

http://www.w3.org/2001/XMLSchema#string

Bruno Chauffert

http://www.w3.org/2001/XMLSchema#string

Carmen Garrido

http://www.w3.org/2001/XMLSchema#string

Dominique Cathelin

http://www.w3.org/2001/XMLSchema#string

Elise Schmitt

http://www.w3.org/2001/XMLSchema#string

François Ghiringhelli

http://www.w3.org/2001/XMLSchema#string

Nicolas Larmonier

http://www.w3.org/2001/XMLSchema#string

P304

336-344

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/EJI.200324181

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

34

http://www.w3.org/2001/XMLSchema#string

P50

François Ghiringhelli

Bruno Chauffert

François Martin

P577

2004-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8881859

http://www.w3.org/2001/XMLSchema#string

P698

14768038

http://www.w3.org/2001/XMLSchema#string

P921